// App-Quantinova.ai

Abstract 57 : Reduction in Ischemic Stroke With Icosapent Ethyl - Insights From REDUCE-IT

Researchers

Presenter

  • Deepak L Bhatt

Principal Investigators

  • Philippe G Steg

  • Michael Miller

  • Eliot A Brinton

  • Terry A Jacobson

  • Steven Ketchum

  • Rebecca Juliano

  • Lisa Jiao

  • Ralph Doyle

  • Craig Granowitz

  • Jean-Claude Tardif

  • John Gregson

  • C. Michael Gibson

  • Megan C Leary

  • Christie M Ballantyne

Medical Centers

  • Brigham and Womens Hosp Heart & Vascular Cntr and Harvard Med Sch, Boston, MA

  • Université de Paris, AP-HP (Assistance Publique-Hôpitaux de Paris); Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), INSERM U-1148, Paris, France

  • Dept of Neurology, Univ of Maryland Sch of Medicine, Baltimore, MD

  • Utah Lipid Cntr, Salt Lake City, UT

  • Office of Health Promotion and Disease Prevention, Dept of Medicine, Emory Univ Sch of Medicine, Atlanta, GA

  • Amarin Pharma, Inc., Bridgewater Township, NJ

  • Montreal Heart Institute, Universite Montreal, Montreal, QC, Canada

  • London School of Hygiene and Tropical Medicine, London, United Kingdom

  • Harvard Clinical Rsch Institure, Boston, MA

  • Dept of Neurology, Lehigh Valley Hosp and Health Network, Allentown, PA

  • Dept of Medicine, Baylor College of Medicine; Cntr for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Cntr, Houston, TX

Locations

  • United States

  • France

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

  • Genetic Disorder

Disease

  • Myocardial infarction

  • Ischemic stroke

  • Angina

  • Coronary Artery Disease

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Icosapent ethyl

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved